The medical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 receptor that’s demonstrating significant promise in clinical trials for managing obesity. Unlike some existing weight loss approaches, retatrutide appears to provide a significant substantial loss in body weight and benefit metabolic function, pa